Drugs /

siremadlin

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. HDM2 inhibitor HDM201 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.

Clinical Trials

View Clinical Trials for siremadlin

Siremadlin has been investigated in 6 clinical trials, of which 5 are open and 1 is closed. Of the trials investigating siremadlin, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

BRAF Fusion, BRAF Mutation, and CCND1 Amplification are the most frequent biomarker inclusion criteria for siremadlin clinical trials.

Acute myeloid leukemia, colorectal carcinoma, and malignant solid tumor are the most common diseases being investigated in siremadlin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Siremadlin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Siremadlin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating siremadlin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hdm201, nvp-hdm 201
Drug Target(s) [2]:
MDM2
NCIT ID [1]:
C116325

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.